



NEWS

TOPICS & PROJECTS

PODCASTS

NEWSLETTERS

ABOUT

SUPPORT

Topics: [Anthrax](#)



SHARE

Feb 1, 2002 (CIDRAP News) BioPort Corp of Lansing, Mich., yesterday received Food and Drug Administration (FDA) approval to begin routine distribution of its anthrax vaccine after more than 3 years of effort to bring its operation up to federal standards.

"FDA is now satisfied that BioPort's renovated facility can produce a vaccine that meets FDA standards for safety and efficacy," the agency said in a news release.

The FDA said it completed the clearance process yesterday by approving Hollister-Stier Laboratories, Spokane, Wash., as BioPort's contractor to fill vials with the anthrax vaccine. The agency had inspected Hollister-Stier's plant Jan 7 through 10, and had inspected and approved BioPort's manufacturing plant in December 2001.

BioPort, the only US producer of anthrax vaccine, makes the vaccine for the Department of Defense (DoD). The company was formed in 1998 to buy the manufacturing plant from the state of Michigan. The firm completed a plant renovation after the purchase and has been working since then to gain FDA approval of the operation; the vaccine itself was licensed by the FDA in 1970.

The FDA also announced it has released three lots of vaccine that were submitted for inspection in support of the license supplements for the plant renovation and Hollister-Stier's filling operation. Each lot of anthrax vaccine is tested for purity, potency, identity, and sterility by the FDA's Center for Biologics Evaluation and Research, the FDA noted.

All vaccine produced at the plant is owned by the Defense Department, company officials noted. More than half a million US troops have received the vaccine since a program to vaccinate all military personnel began in 1998. Because of a shortage of vaccine related to the delayed approval of BioPort's facility, the vaccination program was cut back in 2000 to focus only on troops considered to be at highest risk for anthrax exposure.

A DoD statement released yesterday said, "The department will continue to protect designated special mission units with the anthrax vaccine and is undertaking a thorough review of all factors to decides its future use of the vaccine. In doing so, the department's healthcare leaders have been consulting with the Department of Health and Human Services regarding possible civilian needs for the vaccine." Officials said they will make an announcement soon about the department's anthrax vaccination policy.

In December, the Department of Health and Human Services acquired thousands of doses of anthrax vaccine made in the renovated BioPort plant for possible civilian use. The vaccine was offered as an extra precaution to postal and government employees who had been exposed to anthrax in last fall's anthrax attacks, but few accepted the offer.

In welcoming the FDA's approval, BioPort President Robert Kramer commented in a press release, "Our 220 employees have kept their sense of dedication and focus for three years to get to this day. They've worked around the clock, and they've made countless personal sacrifices to gain this approval because they realize how vital the vaccine is to the protection of our military personnel."

See also:

Department of Defense statement on the BioPort licensure
http://www.defenselink.mil/news/Jan2002/b01312002_bt047-01.html

RELATED NEWS

[GAO says Defense Department lagging on lab biosecurity](#)

September 21, 2018
Stephanie Soucheray | News Reporter | CIDRAP News



[Infectious disease field loses 'commander-in-chief' D.A. Henderson](#)

August 22, 2016
Lisa Schnirring | News Editor | CIDRAP News



[FedEx bans select agents after DoD anthrax lapses](#)

July 30, 2015
Robert Roos | News Editor | CIDRAP News



[CDC: DoD anthrax errors involved 575 shipments](#)

July 28, 2015
Robert Roos | News Editor | CIDRAP News



THIS WEEK'S TOP READS

1

[Risk of heart attack, stroke drops after COVID vaccination, data show](#)

As seen in other studies, there was a higher incidence of thrombocytopenia after first dose of AstraZeneca compared with no vaccination.
Stephanie Soucheray | July 31, 2024



2

[Previously undetected H5N1 avian flu cases in farmworkers revealed in new report](#)

The investigators also cultured infectious H5N1 virus from milk and cattle samples taken from 2 Texas dairy farms.
Jim Wappes | August 1, 2024





- NEWS
- TOPICS & PROJECTS
- PODCASTS
- NEWSLETTERS
- ABOUT

4 after COVID infection, data suggest

Participants with diabetes had higher odds of both hearing loss and sensorineural hearing loss.

Mary Van Beusekom | July 30, 2024



5 Mpox cases spiking in 10 African nations

Some of the cases have been caused by what researchers are calling "clade 1b," a new mpox lineage identified in the DR Congo last year that is highly transmissible.

Stephanie Soucheray | August 2, 2024



6 Experts consider H5N1 avian flu unknowns as state fairs loom

So far, humans who have been infected with H5N1 via contact with infected cows have also exhibited mild illness.


Stephanie Soucheray | July 29, 2024



7 WHO considers public health emergency as mpox cases mount in Africa

Over the weekend South Africa said it now has 22 cases of the virus.


Stephanie Soucheray | August 5, 2024



8 WHO warns of increase in hypervirulent, multidrug-resistant Klebsiella strains

The WHO is particularly worried about ST23, an hvKp strain that carries carbapenem-resistance genes and has been detected in 12 countries.

Chris Dall | August 1, 2024



9 CDC urges livestock workers get seasonal flu vaccine to cut pandemic risk

The CDC is offering support for targeted programs and vaccine supplies to states, part of a plan to cut the risk of H5N1 reassortment with seasonal flu.

Lisa Schnirring | July 30, 2024



10 Study spotlights psychiatric, cognitive problems years after severe COVID-19

Notably, 95 of 353 participants (27%) reported occupational change.

Stephanie Soucheray | August 1, 2024



Choose newsletters

- ☐ Select all
- ☐ Daily Headlines
- ☐ Antimicrobial Stewardship Newsletter
- ☐ Chronic Wasting Disease Newsletter
- ☐ Flu Vaccine Roadmap Newsletter
- ☐ Resilient Drug Supply Newsletter

Email address

SUBSCRIBE

OUR UNDERWRITERS

UNRESTRICTED FINANCIAL SUPPORT PROVIDED BY



Principal Underwriter



Leading Underwriter



Major Underwriter



Supporting Underwriter

BECOME AN UNDERWRITER



NEWS

TOPICS & PROJECTS

PODCASTS

NEWSLETTERS

ABOUT

Contact Us

CIDRAP - Center for Infectious Disease Research & Policy
Research and Innovation Office, University of Minnesota, Minneapolis, MN

EMAIL US

© 2024 Regents of the University of Minnesota. All rights Reserved.
The University of Minnesota is an equal opportunity educator and employer

Research and Innovation Office | Contact U of M | Privacy Policy

Choose newsletters

- Select all
- Daily Headlines
- Antimicrobial Stewardship Newsletter
- Chronic Wasting Disease Newsletter
- Flu Vaccine Roadmap Newsletter
- Resilient Drug Supply Newsletter

NEWSLETTERS